Home Capabilities Inizio Medical Cell & gene therapy

Cell & gene therapy: It’s in our DNA

Scroll

Cell and gene therapies are disrupting medicine at every level.

For patients, they represent the promise of curative treatment. Healthcare professionals are excited by their potential but daunted by the upheaval of long-established practices. And for payors, they demand entirely new models of assessing value that need to be established.

Bringing these transformative therapies to market is a journey unlike any other, with rapidly changing expectations and an experienced navigator is essential to achieving success in this journey.

Industry-leading expertise.

We understand the challenges in bringing cell and gene therapies to market.

127

cell & gene therapy assets
worked on

119

in-house staff experienced in cell & gene therapy

58

novel cell, viral, and non-viral technology platforms within our expertise

30

live clients with cell & gene therapy assets

24

people with PhDs and/or postdoctoral experience in cell & gene therapy

3

patient owners in cell & gene therapy

Our Services.

We have an unrivaled cross-discipline team of specialists, who can offer the following services:

Medical Analytics

We help address your most critical challenges through the synergistic combination of medical strategy services, advanced analytics, and digital innovation. We cut through data, opinions, and noise to cultivate actionable insights, bringing together our core areas of expertise to uncover true value at every step.

Investor Relations

Whether you are moving from clinical development to commercialisation, or have an avid IR following to manage, every decision, every hire, every communication matters more than ever before.

Market Access and HEOR

‘Once and done’ curative therapies have an intrinsically different value to other medicines. This changes both the way that value needs to be presented, and the data required to measure and convey it.

Strategic Communications

The very concept of your therapy is revolutionary and could be at odds with the clinical status quo. Preparing the clinical community for this disruption requires a sea-change in your strategy, planning and tactics.

Commercialization strategy

Expectations are high, and hope is palpable; patients and their HCPs want your therapy to succeed. Managing all of this and delivering on their (and your) aspirations, requires a new, transparent and collaborative commercialization approach.

Medical and Regulatory Affairs

We design and deliver customized approaches to accelerate the achievement of your goals and drive transformation within Medical Affairs. Our strategic mindset, analytical skills, therapeutic area knowledge, and understanding of best practices ensure that we create solutions that are meaningful, achievable, and measurable.

Our Experience.

Bringing the innovative cell and gene therapies to market is a journey unlike any other, with changing expectations along the way. We understand the challenges in bringing cell and gene therapies to market.

For patients, they represent the promise of curative treatment. Healthcare professionals are excited by their potential but daunted by the upheaval of long-established practices. And for payors, they demand entirely new models of assessing value that need to be established.

We have supported products across vector and delivery modalities, and understand the science.

  • Viral vector therapy
    • AAV
    • Lentivirus
    • Adenovirus
    • Vaccinia virus
  • RNA-based therapy
    • Knockdown
    • Augmentation
    • Exon skipping
  • Cell therapy
    • Allogenic stem cells
    • Skin grafts
    • Pluripotent auditory neurons
    • CAR T-cell and TCR T-cells

GenEra.

Built with expertise from across Inizio Medical, our GenEra team can help you navigate the journeys ahead by providing a wealth of practical assistance to guide you through approval, maximize access, and drive adoption.

Ultimately, we help ensure patients receive and benefit from your innovative therapies.

Our GenEra Consulting team

Matt Booth

Senior Vice President,
Global Therapy Lead

Rachel Hatfield

Managing Partner

Sarah Waterson

Business Lead

Sam Falsetti

Global Chief Biotechnology Officer, Inizio Medical

Brandon Boland

Senior Director,
Portfolio Lead

Frank Sah

Vice President,
Translational/HEOR Strategy

Your market-leading commercialization partner.

Leveraging our connected suite of capabilities, our experts will guide you through each pivotal moment in your asset’s lifecycle, creating tailored solutions that simplify the complex, unlock value, and enhance treatment outcomes.